NurExone moves towards human clinical trials, completes pre-IND meeting with FDA

Health Care, The Watchlist

NurExone Biologic Inc. (TSXV:NRX) has completed a pre-investigational new drug meeting with the U.S. FDA regarding its exotherapy product.

TSXV:NRX

1 min

NurExone Biologic Inc. (TSXV:NRX) (FSE:J90), a biopharmaceutical company developing biologically guided exosome therapy for patients with traumatic spinal cord injuries, has announced that it has completed a pre-investigational new drug meeting with the U.S. Food and Drug Administration in connection with the manufacturing, preclinical and clinical development plan of ExoPTEN, NurExone’s first exotherapy product, after receiving a written response from the FDA on Aug. 29.

This is sponsored content issued on behalf of NurExone Biologic Inc., please see full disclaimer here.

Join the discussion: Find out what everybody’s saying about this stock on the NurExone Biologic Inc. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

Inflation concerns, lofty valuations, and growing uncertainty around returns from have prompted investors to reassess their AI exposure.

Kits Eyecare (TSX:KITS) notched record sales over Black Friday and Cyber Monday, building conviction in its track record of profitable growth.

In the newest edition of Stockhouse's Weekly Market Movers, a pair of stocks tracking innovative companies aligned with shareholder value.

UniDoc Health Corp. (CSE:UDOC) installed two Health Cubes at Verizon Innovation Labs in Los Angeles and San Francisco, with a third planned.